For primary research manuscripts in the MCI Journal (Articles, Letters, Brief Communications) reporting experiments on live vertebrates and/or higher invertebrates, the corresponding author must confirm that all experiments were performed in accordance with relevant guidelines and regulations. The manuscript must include a statement identifying the institutional and/or licensing committee approving the experiments, including any relevant details. Sex and other characteristics of animals that may influence results must be described. Details of housing and husbandry must be included where they are likely to influence experimental results. We recommend following the ARRIVE reporting guidelines when documenting animal studies (PLoS Bio 8(6), e1000412,2010).
For experiments involving human subjects, authors must identify the committee approving the experiments, and include with their submission a statement confirming that informed consent was obtained from all subjects.
Phase II and III trials
Authors reporting phase II and phase III randomized controlled trials (RCTs) should refer to the CONSORT Statement for recommendations to facilitate the complete and transparent reporting of trial findings. Reports that do not conform to the CONSORT guidelines may need to be revised before formal review.
Clinical trial registration
Prospective clinical trials must be registered before the start of patient enrollment in www.clinicaltrials.gov or a similar public repository that matches the criteria established by ICMJE. A statement including the trial registration must be reported by authors. Further information and documentation to support this should be made available to the Editor on request. (Trials in which the primary goal is to determine pharmacokinetics are exempt.)